Jeffrey Alder
Eloxx Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Bacterial Identification and Susceptibility Testing, Antimicrobial Resistance in Staphylococcus, Antibiotics Pharmacokinetics and Efficacy, Tuberculosis Research and Epidemiology, Microbial Natural Products and Biosynthesis
Most-Cited Works
- → In Vitro Bactericidal Activities of Daptomycin against Staphylococcus aureus and Enterococcus faecalis Are Not Mediated by Inhibition of Lipoteichoic Acid Biosynthesis(2003)88 cited
- → Daptomycin, a new drug class for the treatment of Gram-positiveinfections(2005)61 cited
- → The advance of bacterididal drugs in the treatment of infection(2004)38 cited
- → Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis(2005)37 cited
- → Total synthesis and antifungal evaluation of cyclic aminohexapeptides(2000)37 cited
- → Second-Generation Peptidomimetic Inhibitors of Protein Farnesyltransferase Demonstrating Improved Cellular Potency and Significant in Vivo Efficacy(1999)37 cited
- → Efficacy of A-73209, a potent orally active agent against VZV and HSV infections(1994)21 cited
- → In Vivo Efficacy of ABT-255 against Drug-Sensitive and -Resistant Mycobacterium tuberculosis Strains(1998)20 cited
- → The Use of Daptomycin for Staphylococcus Aureus Infections in Critical Care Medicine(2008)14 cited
- → Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole(1994)9 cited